Settled
Do other lipid agents improve cardiovascular events more than other treatments?
Mostly studied in type 2 & unspecified diabetes. Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Very likely. So far, repeated by independent trials.
NoUnsureYes
- Belief
- 1.00 (range 0.85–1.00)
- Trials for
- 2
- Trials against
- 0
- Inconclusive
- 1
Already under way
- A Registry-based Randomized Controlled Trial of Moderate-intensity Statin Therapy vs. Individualized Low-density Lipoprotein Cholesterol Target-based Therapy…NCT07359105 · recruiting · started 2026
- To Assess the Long-term Efficacy and Safety of Combined Therapy With Ezefeno Tab. in Patients With Dyslipidemia Who do Not Achieve Adequate Control of…NCT06293417 · recruiting · started 2024
- Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus in Prediabetic Patients With…NCT05579626 · enrolling by invitation · started 2023
The evidence so far
- Registered trials
- 50
- With posted results
- 9
- Published papers
- 41
Of 25 decided analyses: 14 favor other lipid agents, 11 find no difference, 0 favor the comparator.
Papers
- Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.Trial report · 2009
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.Trial report · 2023
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.Trial report · 2011
- Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia.Trial report · 2026
- Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.Trial report · 2008
- Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE).Trial report · 2016
Trials
- A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Type 2 DiabetesNCT00618995 · 6 posted results
- A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)NCT00202878 · 4 posted results
- Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects With Type IIb Dyslipidemia With Residual Risk in Addition to Atorvastatin Therapy (FIRST) TrialNCT00616772 · 3 posted results
- Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients: a Randomized Crossover TrialNCT06381947
- ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cARTNCT01683656
- A Prospective, Open-label Study Evaluating the Effects of Probucol Combined with Statins on Atherosclerotic Characteristics and Prognosis in Patients with Ischemic StrokeNCT06604117
- ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)NCT00397657
- Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering TherapyNCT00715273 · 1 posted result